Podcasts about Io

Manufacturers know that automation is table stakes in 2025, and yet it's still a bit of an afterthought for some. You'd think something that can make or break a facility would be everyone's number one priority. And as you'll hear in this episode, overlooking automation can sometimes have disastrous consequences. In this episode, we sit down with Cassy Gardner and Chris Schleich from E Tech Group over virtual Pellegrinos to unpack a real-world case study. They were called in to revive a mothballed solar facility where the owners had accidentally destroyed critical automation infrastructure during demolition. Cut wiring, severed connections, damaged systems... all the stuff they didn't realize was essential until it was gone. The two walk us through everything from why Front-End Engineering and Design (FEED) studies matter (even when you're racing against the clock) to how “humble confidence” became their project philosophy. You'll hear about oversized electrical panels, “pit bull” project managers, and why sometimes the best sales strategy is just showing up when you say you will. In this episode, find out: Why automation often becomes an afterthought in capital projects, and the surprising impact that has How automation may be a small slice of the spend, but determines how the plant runs The most common pitfall manufacturers face when it comes to automation planning What a FEED study is, and why it's essential in fast-paced projects How "humble confidence" and "tenacious politeness" became guiding principles for E Tech What happens when demolition destroys critical wiring and IO connections and how a hazardous monitoring partner failed mid-project Lessons any manufacturer can apply whether that's running a project with 45 people or just five Enjoying the show? Please leave us a review here. Even one sentence helps. It's feedback from Manufacturing All-Stars like you that keeps us going! Tweetable Quotes: “Typically, in a large capital project, the automation budget is around 10%. But it's a really critical 10% that you need to invest to have the manufacturing work the way you want to work.” – Cassy Gardner “Automation relative to mechanical, electrical process, etc. has an outsized impact.”– Chris Schleich “Always start earlier than you think you need to start. If you can engage a partner who is an expert in automation, you will set yourself up for a foundation of success.” – Cassy Gardner Links & mentions: E Tech Group, one of the largest engineering and systems integration companies in the US, providing automation, control and information systems Make sure to visit http://manufacturinghappyhour.com for detailed show notes and a full list of resources mentioned in this episode. Stay Innovative, Stay Thirsty.

Ruby core team member Aaron Patterson (tenderlove) takes us deep into the cutting edge of Ruby's performance frontier in this technical exploration of how one of the world's most beloved programming languages continues to evolve.At Shopify, Aaron works on two transformative projects: ZJIT, a method-based JIT compiler that builds on YJIT's success by optimizing register allocation to reduce memory spills, and enhanced Ractor support to enable true CPU parallelism in Ruby applications. He explains the fundamental differences between these approaches - ZJIT makes single CPU utilization more efficient, while Ractors allow Ruby code to run across multiple CPUs simultaneously.The conversation reveals how real business needs drive language development. Shopify's production workloads unpredictably alternate between CPU-bound and IO-bound tasks, creating resource utilization challenges. Aaron's team aims to build auto-scaling web server infrastructure using Ractors that can dynamically adjust to workload characteristics - potentially revolutionizing how Ruby applications handle variable traffic patterns.For developers interested in contributing to Rails, Aaron offers practical advice: start reading the source code, understand the architecture, and look for ways to improve it. He shares insights on the challenges of making Rails Ractor-safe, particularly around passing lambdas between Ractors while maintaining memory safety.The episode concludes with a delightful tangent into Aaron's latest hardware project - building a color temperature sensor for camera calibration that combines his photography hobby with his programming expertise. True to form, even his leisure activities inevitably transform into coding projects.Whether you're a seasoned Ruby developer or simply curious about language design and performance optimization, Aaron's unique blend of deep technical knowledge and playful enthusiasm makes this an engaging journey through Ruby's exciting future.Send us some love. HoneybadgerHoneybadger is an application health monitoring tool built by developers for developers.JudoscaleAutoscaling that actually works. Take control of your cloud hosting.Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the show

Topics covered in this episode: * Mozilla's Lifeline is Safe After Judge's Google Antitrust Ruling* * troml - suggests or fills in trove classifiers for your projects* * pqrs: Command line tool for inspecting Parquet files* * Testing for Python 3.14* Extras Joke Watch on YouTube About the show Sponsored by us! Support our work through: Our courses at Talk Python Training The Complete pytest Course Patreon Supporters Connect with the hosts Michael: @mkennedy@fosstodon.org / @mkennedy.codes (bsky) Brian: @brianokken@fosstodon.org / @brianokken.bsky.social Show: @pythonbytes@fosstodon.org / @pythonbytes.fm (bsky) Join us on YouTube at pythonbytes.fm/live to be part of the audience. Usually Monday at 10am PT. Older video versions available there too. Finally, if you want an artisanal, hand-crafted digest of every week of the show notes in email form? Add your name and email to our friends of the show list, we'll never share it. Michael #1: Mozilla's Lifeline is Safe After Judge's Google Antitrust Ruling A judge lets Google keep paying Mozilla to make Google the default search engine but only if those deals aren't exclusive. More than 85% of Mozilla's revenue comes from Google search payments. The ruling forbids Google from making exclusive contracts for Search, Chrome, Google Assistant, or Gemini, and forces data sharing and search syndication so rivals get a fighting chance. Brian #2: troml - suggests or fills in trove classifiers for your projects Adam Hill This is super cool and so welcome. Trove Classifiers are things like Programming Language :: Python :: 3.14 that allow for some fun stuff to show up in PyPI, like the versions you support, etc. Note that just saying you require 3.9+ doesn't tell the user that you've actually tested stuff on 3.14. I like to keep Trove Classifiers around for this reason. Also, License classifier is deprecated, and if you include it, it shows up in two places, in Meta, and in the Classifiers section. Probably good to only have one place. So I'm going to be removing it from classifiers for my projects. One problem, classifier text has to be an exact match to something in the classifier list, so we usually recommend copy/pasting from that list. But no longer! Just use troml! It just fills it in for you (if you run troml suggest --fix). How totally awesome is that! I tried it on pytest-check, and it was mostly right. It suggested me adding 3.15, which I haven't tested yet, so I'm not ready to add that just yet. :) BTW, I talked with Brett Cannon about classifiers back in ‘23 if you want some more in depth info on trove classifiers. Michael #3: pqrs: Command line tool for inspecting Parquet files pqrs is a command line tool for inspecting Parquet files This is a replacement for the parquet-tools utility written in Rust Built using the Rust implementation of Parquet and Arrow pqrs roughly means "parquet-tools in rust" Why Parquet? Size A 200 MB CSV will usually shrink to somewhere between about 20-100 MB as Parquet depending on the data and compression. Loading a Parquet file is typically several times faster than parsing CSV, often 2x-10x faster for a full-file load and much faster when you only read some columns. Speed Full-file load into pandas: Parquet with pyarrow/fastparquet is usually 2x–10x faster than reading CSV with pandas because CSV parsing is CPU intensive (text tokenizing, dtype inference). Example: if read_csv is 10 seconds, read_parquet might be ~1–5 seconds depending on CPU and codec. Column subset: Parquet is much faster if you only need some columns — often 5x–50x faster because it reads only those column chunks. Predicate pushdown & row groups: When using dataset APIs (pyarrow.dataset) you can push filters to skip row groups, reducing I/O dramatically for selective queries. Memory usage: Parquet avoids temporary string buffers and repeated parsing, so peak memory and temporary allocations are often lower. Brian #4: Testing for Python 3.14 Python 3.14 is just around the corner, with a final release scheduled for October. What's new in Python 3.14 Python 3.14 release schedule Adding 3.14 to your CI tests in GitHub Actions Add “3.14” and optionally “3.14t” for freethreaded Add the line allow-prereleases: true I got stuck on this, and asked folks on Mastdon and Bluesky A couple folks suggested the allow-prereleases: true step. Thank you! Ed Rogers also suggested Hugo's article Free-threaded Python on GitHub Actions, which I had read and forgot about. Thanks Ed! And thanks Hugo! Extras Brian: dj-toml-settings : Load Django settings from a TOML file. - Another cool project from Adam Hill LidAngleSensor for Mac - from Sam Henri Gold, with examples of creaky door and theramin Listener Bryan Weber found a Python version via Changelog, pybooklid, from tcsenpai Grab PyBay Michael: Ready prek go! by Hugo van Kemenade Joke: Console Devs Can't Find a Date

A bright star and planet team up with the Moon early tomorrow to form a tight, beautiful triangle. Pollux will stand close to the lower left of the Moon, with much brighter Jupiter about the same distance to the lower right of the Moon. Pollux is the brightest star of Gemini, while Jupiter is a planet. Jupiter is by far the giant of the solar system. It’s more than twice as massive as all the other planets combined. And it’s about 11 times the diameter of Earth. That makes it big enough to hold 1300 Earths. But a recent study says that Jupiter might have been much bigger during its infancy – about two or two-and-a-half times its current diameter. That would have made it big enough to hold thousands of Earths. Scientists came to that conclusion by studying the orbits of two of Jupiter’s small, close-in moons. The orbits are slightly tilted. Simulations showed that the moons were pushed into those orbits by the larger moon Io as it moved away from Jupiter. Those calculations revealed Jupiter’s original size and other details. Jupiter probably formed in just a few million years – much quicker than most of the other planets. By then, the supply of planet-making materials had dried up. So Jupiter’s gravity began squeezing it and making it spin faster. Eventually, the planet reached a point where it couldn’t shrink any farther – leaving the smaller but still-giant world we see today. Script by Damond Benningfield

Skulk! Comedian! Musician! Story-teller! Friend! Delight! More! Skulk and I have a great chat about this project and more! THE MANY INCESSANT LIVES & SUBSEQUENT DEATHS DESERVED OF SKULK, The HULKING is a fictional video podcast built on music, performance, storytelling, and Ai visuals. Following the War to End All Wars and having depleted most of our resources, all people - by choice or by force - move to The City That's Always Falling Apart to try and stave off extinction. Giant forces inhabiting this final city both personify our desires and attempt to sway our fates, but an oafish beast known as Skulk tries to save us all. At times dark, goofy, aggressive, honest, and full of hope, The Many Incessant Lives and Subsequent Deaths Deserved of Skulk, The Hulking explores the decisions we make as a people - an allegory for our globalized world, the weaponization of capitalism, and the age-old ‘problem' of the human condition. Skulk, The Hulking is an ogre-like dolt trying to help a world that has fallen apart, yet he seems only to find unique paths to an early demise, while an Earth - knowing unfortunately that he's the planet's last hope - keeps bringing him back to life. He is a giant force that represents us all, trying to figure things out, wading through the muckiest parts of life, fighting the forces that none of us have the energy to fight against, making the choices none of us wants to make, failing miserably, like all of us probably would. No one even wants him to do it but man, his hope just can't be killed…or maybe he's just an idiot. In this story, things are rarely all-bad or all-good. The audience is asked whether they approve of the reasons they do what they do and if the ends justify the means.  Characters in the podcast originally appeared in Skulk (the band's) live shows and music videos. Lady Baghead and the Followers of Baghead were originally depictions of Rene Magritte's surrealist painting “The Lovers”. Hammerhands, a wrecking ball of hate with hammers for hands was played in Skulk music videos by Henry Zebrowski (Last Podcast on the Left, Wolf of Wall Street). And Camelman - originally a prancing merrymaker in a camel mask who pulled popsicles from his whitey tighties and handed them to the concert crowd - has evolved into the gangly overlord of our tantilizing addictions. With visuals created using MidJourney, the ‘near misses' of Ai creation become a style. When creating with Ai, it is nearly impossible to recreate the same exact character with subsequent prompts. Yet since Skulk is constantly dying and being re-born out of whatever material the earth can find at the time, these glitches are given context and woven into the tale. The differing looks of the central characters becomes commentary on how we all appear differently based on the observers' biases, and of course all Ai is ‘nurtured' by our culture's biases. Each podcast episode ends with Ai-altered music videos from Skulk (the band). Says Skulk (the artist) “I believe people fight against Generative Ai for the wrong reasons. It is a tool. How, not if it is used is the question. I believe what people actually want is regulation of Ai.  It is when it can be used for harm that it gets sketchy.” The goal is to help the audience question, with a mind further-opended, why those in power, their enemies, and they themselves do and believe the things they do and believe.  MORE ABOUT SKULK: Skulk, The Hulking (Steve Pasieka) is a multifaceted artist whose creative journey spans music, comedy, and technology. Part of Chicago's improv scene in the early 2000s, he eventually co-founded the improv group pH. His commitment to his craft led him to train at renowned institutions iO and The Annoyance, eventually joining the iO house team, The Chorus, and earning coaching by improv legend Noah Gregoropoulos. After moving to New York, Skulk transitioned to music, founding Skulk, The Hulking - fusing theatrical performance, socio-political lyrics and dark electronic beats. Opening for iconic musicians like Capadonna of Wu-Tang Clan and C-Knowledge of Digable Planets, the project grew to a full band releasing three albums. Recently, Skulk has become a skilled user of AI tools, creating images through MidJourney, animating visuals with MotionLeap, and exploring the artistic potential of generative AI. He believes that AI, like any tool, is only as good as the meaning and care you put into it, which he explores in his most recent project. The Many Incessant Lives and Subsequent Deaths Deserved of Skulk, The Hulking brings together many facets of Skulk's past work in a fictional video podcast built on music, performance, Ai and storytelling. AND THIS IS ONLY THE FIRST HALF OF OUR CHAT! For part two, subscribe via Apple Podcasts OR simply click on over here to Patreon.

ぬるぽ放送局おたより投稿フォーム https://forms.gle/6tbmBzK6wbyavJG47 2025年9月パワープレイ 「U.N.オーエンはXSなのさ？」 編曲：gaburyu 原曲：東方紅魔郷 / U.N.オーエンは彼女なのか？ 収録アルバム：TOHO BOOTLEGS 9 2025・5・5 Release https://www.iosysos.com/discographyportal.php?cdno=IO-0341 番組時間：89分33秒 出演者：夕野ヨシミ、たくや VOICEVOX:ずんだもん VOICEVOX:四国めたん ---- 2025/9/11に公開録音したものを配信いたします。 ラジオ記事はリスナーのEEチャンピオンさんが書いてくれているので楽してます。 ＜オープニング＞ ・もう二度とない1044回 ・一番良かった回は、出てこない ・2週間ぶりの生放送です ・ずーっとすき家の話してた ・いつも間にいなくなる初見の方 ・イオシス最新情報 ・テラリアが楽しくてしかたない ・楽曲提供のお知らせ 　【スタスト】コラボ記念曲『星の島の出会い』feat. 初音ミク 　ボーカル：初音ミク 　作詞：DD"ナカタ"Metal 　作編曲：uno(IOSYS) 　ギター実演：NUE ・【スペシャルMV】 一旦お月見チキラー / 不破湊 【一旦ステイ TONIGHT】 ・食べ美がまたやってましたね ・楽曲提供のお知らせ 　「ばーさすわーるど／天川はの」 　作詞：まろん (IOSYS) 　作編曲：まろん & ARM (IOSYS) ・フィンランドから無事に帰ってきました ・もう、全部D.wattなんだよな ・イオシスチャンネル開設19周年 ・チルパ990万再生 ・タイトーさんのお知らせ 　イオシスがシナリオ制作しているNintendo Switchゲーム『QQQbeats!!!』が　　　　　　　2025/9/18リリース！いますぐ予約購入しよう！ ・Nintendo Switchごと買ってください ・ラフさん100歳だね ・9月10月もたくさんイベントあります ・10/25　トークライブイベントあります ・パビリオンとは ・万博みたーい ・今年も特別ドリンク用意してます ・のれんドリンク ・結婚の予定がないので確認してないです ＜Aパート＞ ・ふつおたです ・メルヘンデビューが1曲目 ・デレマスイオシス曲をたくさん再生させて運営を怖がらせましょう ・そうか安部さんだった ・1万円！？ ・CDプレイヤー持ってない人は買ってください ・日記のコーナー宛 ・2巻だけ読んで帰路へ ・靴は3000円以上のものを買おうね ・10年以上履ける厚底の靴 ・空港で必ず検査される厚底の靴 ・厚底のわらじ ・沖縄転勤が決まりました ・水中はいいぞ ・なんで靴トークでこんなに時間保たせられるの ・靴おたのコーナー ・冬の間は沖縄に住みたい ・一旦ステイで30年 ・高温多湿が悪い文明 ・偽りの秋雨前線 ・毎日入院しているみたいですね ・裸でいいのでは？ ・コヨちゃんは半裸族 ・新しいのは性能がいい ・USBは統一してほしい ・人生初のお便りメール ・お誕生日おめでとうございます ・免許合宿とは ・免許は若いうちに取っといた方がいい ・800回は5年前 ・これ、今ならフォトショで作れちゃうな ・モデルさんの撮影会に行きたいのでカメラを買いました ・衣装にオプションとかあるんだ ＜Bパート＞ ・D.wattもいい年ですから ・みつをたです ・シャットダウンだって言ってるのに再起動 ・３Dプリンターで何を出力します？ ・３D厚底って、普通なんだよな ・褐色エジプト猫耳口リ ・明日はニンダイ ・シーシャ吸ってる場合じゃねー ・シーシャダイレクト ・30年何も問題のなかった井森美幸 ・週刊誌の末尾みたいな内容 ・こよこよする ・ミオしゃのソロライブ ・残念チャージマン研でした ・日清食品は恐ろしいですね ・チャージマン研みたいな寝癖ができてた ・お腹に爆弾を抱えている跡部博士 ＜エンディング＞ ・新作の何かを作りたいけど、続報がなかったら忘れてください ・阪神優勝しましたね ・どうして道頓堀に飛び込んでしまうのか ・大阪万博盛り上がってますね ・3連休なんだ ・夕野ヨシミは家にいます ・あ、すすきのに呼ばれてるんだった

出演者： miko、quim 配信ペース： 隔週水曜日 番組時間：111分15秒 ♯本番組はリモート収録です。 ♯収録時環境の影響により、全体的に聴き取り辛くなっております。 　申し訳ございません。 mikoラジ、第380回です。 暑さやゲリラ豪雨と忙しい日々ですが、400回が見え始めても変わらぬ『お家ラジオ』。 忙しい日々だったり健康のことだったり、勉強の仕方について等々……？ 話題がアレコレ、井戸端会議みたいなノリなので時間も長々（汗） それでもmikoラジは続いているんだなぁ……（遠くを見つめる編集人）。 最後までごゆるりと、用法用量を守ってお楽しみくださいませ。 ♯途中で色々とノイズ等入りますが、収録時のものです。 　ご安心ください、お手持ちの機器は正常です。 //////////////////// VOICEVOX:ずんだもん VOICEVOX:四国めたん //////////////////// -------------------- ●お便り募集中！ mikoラジでは以下の内容でお便りを募集中です！ ・ふつおた 　／普通のお便り、お待ちしています！ ・mikoは大変な絵を描いていきました 　／miko画伯に描いて欲しいお題をお待ちしています！ ・メシヲコエテ 　／料理人・mikoに教えて欲しいレシピをお待ちしています！ bit.ly/2GAWjyv 投稿フォームからラジオに投稿が出来ます！ コーナー名を選び、メッセージ・ラジオネーム・お所を入力して、 どんどん送ってください！　お待ちしています！！ ------------ 本ラジオのメインパーソナリティーである「チーム我等(miko/quim)」、 それぞれ以下個人サークルにて活動中です。 ・miko：miko ・quim：SHIGANAI RECORDS（ shiganai.com/ ） 活動詳細については、上記HPの他 各人のブログ/twitter等にて随時告知しておりますので、チェックしてみてください！ ・みころぐ。(mikoのブログ)（ ameblo.jp/miko-nyu/ ） ・@ mikonyu(mikoのtwitter)（ twitter.com/mikonyu ） ・@ quim(quimのtwitter)（ twitter.com/quim ） --- その他の活動については、以下のとおりです！ -- チーム我等がメインクルーとして活動していた「アルバトロシクス（ albatrosicks.com/ ）」、 これまでリリースしたCDは、イオシスショップ（ iosys.booth.pm/ ）にて頒布しております。ご興味ある方は是非！ ---------- ☆2025年9月IOSYSはいてない.comパワープレイ楽曲 03. U.N.オーエンはXSなのさ？ 編曲：gaburyu 原曲：東方紅魔郷 / U.N.オーエンは彼女なのか？ 収録アルバム：TOHO BOOTLEGS 9 2025・5・5 Release https://www.iosysos.com/discographyportal.php?cdno=IO-0341 誰にでも、クラブで聴きたい「メロ」がある。 イオシスが手がける、最新型東方クラブミュージックアレンジシリーズ！ 「唯一無二の【現場主義】スタイル」をテーマに贈る東方クラブアレンジ・コンピレーション第9弾！ 長きにわたり実力派のプロデューサー陣と共にお届けしたシリーズは、節目の⑨作に至ってついに完結へ。 「ここで踊っていることこそが、僕らにとっての幻想郷なのかもしれない」 音楽は終わらない。たとえ陽が昇っても、まるで明けない夜が続いていくみたいに。

We are refunding all purchases of the Glitch Report premium edition and we hope you look forward to our updated DLC and content roadmap plans in the future.This week we talk about the IO's failed partners program, the unfinished Wolfenstein trilogy, Hollow Knight: Silksong, and more!Find GnittWitt on the net⁠https://linktree.com/gnittwitt⁠⁠⁠⁠⁠⁠⁠⁠⁠

Io sono Francesco Cecchetti, consulente paesaggistico e agronomico e aiuto le persone a fiorire insieme al proprio giardino. Stai ascoltando Giardino Rivelato, da cinque anni il podcast per chi crede fermamente che tutte le persone hanno bisogno di un giardino.Sogni un prato perfetto che non ha bisogno di acqua, di essere tagliato o curato? L'idea di un prato sempre verde, immune al caldo e alla siccità, è allettante, ma dietro questo sogno si nasconde un'amara verità. Quali sono i costi nascosti del prato sintetico? Che impatto ha il prato sintetico sulle nostre vite? Cosa lo rende una scelta sbagliata? Se sogni un giardino sempre verde e senza sforzo, il prato sintetico sembra la soluzione perfetta. Ma è davvero così? Dietro la promessa di un verde eterno si nasconde una realtà fatta di impatti ambientali, costi nascosti e un'assenza di vita.Sostieni e finanzia Giardino Rivelato: https://www.patreon.com/francescocecchetti Vieni a trovarmi su giardinorivelato.it

Il tuo sito può perdere il 90% di traffico in una notte: è già successo a tanti.Google sta cannibalizzando i contenuti con l'AI Overview: risultato? Crolli del traffico fino al 40% su Business Insider e CNN, l'1% degli utenti clicca sulle fonti. Basta una funzione per trasformare Internet in un feudo chiuso, dove solo i big sopravvivono. L'ecosistema che fa vivere blog e progetti indipendenti rischia di sparire entro 12 mesi, se resta questa rotta.Siamo pronti a barattare tutta la diversità del web solo per un po' di comodità? ~~~~~ INGAGGI E SPONSORSHIP ~~~~~ Per contatti commerciali: sales@matteoflora.comPer consulenze legali: info@42LawFirm.it~~~~~ SOSTIENI IL CANALE! ~~~~~Con la Membership PRO puoi supportare il Canale » https://link.mgpf.it/proSe vuoi qui la mia attrezzatura » https://mgpf.it/attrezzatura~~~~~ SEGUIMI ANCHE ONLINE CON LE NOTIFICHE! ~~~~~» CANALE WHATSAPP » https://link.mgpf.it/wa» CANALE TELEGRAM » https://mgpf.it/tg» CORSO (Gratis) IN FUTURO » https://mgpf.it/nl» NEWSLETTER » https://mgpf.it/nl~~~~~ CIAO INTERNET E MATTEO FLORA ~~~~~ Questo è “Ciao Internet!” la prima e più seguita trasmissione di TECH POLICY in lingua italiana, online su YouTube e in Podcast.Io sono MATTEO FLORA e sono:» Professore in Fondamenti di Sicurezza delle AI e delle SuperIntelligenze (ESE)» Professore ac in Corporate Reputation e Crisis Management (Pavia).Sono un Imprenditore Seriale del digitale e ho fondato:» The Fool » https://thefool.it - La società italiana leader di Customer Insight» The Magician » https://themagician.agency - Atelier di Advocacy e Gestione della Crisi» 42 Law Firm » https://42lf.it - Lo Studio Legale per la Trasformazione Digitale » ...e tante altre qui: https://matteoflora.com/#aziendeSono Future Leader (IVLP) del Dipartimento di Stato USA sotto Amministrazione Obama nel programma “Combating Cybercrime (2012)”.Sono Presidente di PermessoNegato, l'associazione italiana che si occupa di Pornografia Non- Consensuale e Revenge Porn.Conduco in TV “Intelligenze Artificiali” su Mediaset/TgCom.

In this episode, Will Wilson, CEO and co-founder of Antithesis, explores Deterministic Simulation Testing (DST) with host Sriram Panyam. Wilson was part of the pioneering team at FoundationDB that developed this revolutionary testing approach, which was later acquired by Apple in 2015. After seeing that even sophisticated organizations lacked robust testing for distributed systems, Wilson co-founded Antithesis in 2018 to make DST commercially available. Deterministic simulation testing runs software in a fully controlled, simulated environment in which all sources of non-determinism are eliminated or controlled. Unlike traditional testing or chaos engineering, DST operates in a separate environment from production, allowing for aggressive fault injection without risk to live systems. The key breakthrough is perfect reproducibility -- any bug found can be recreated exactly using the same random seed. Antithesis built "The Determinator," a custom deterministic hypervisor that simulates entire software stacks including virtual hardware, networking, and time. The system can compress years of stress testing into shorter timeframes by running simulations faster than wall-clock time. All external interfaces that could introduce non-determinism (network calls, disk I/O, system time) are mocked or controlled by the simulator. The approach has proven effective with major organizations including MongoDB, Palantir, and Ethereum. For Ethereum's critical "Merge" upgrade in 2022, Antithesis found and helped fix several serious bugs that could have been catastrophic for the live network. The platform typically finds bugs that traditional testing methods miss entirely -- such as those arising from rare race conditions, complex timing issues, and unexpected system interactions. This episode is sponsored by Monday Dev

durée : 00:13:55 - Les Midis de Culture - par : Marie Labory - Pour son nouveau roman, "Les Forces", la poétesse Laura Vazquez reprend les codes du roman d'apprentissage. Elle retrace de façon chronologique le parcours d'une narratrice, qui, de l'enfance à l'âge adulte, traverse cinq différentes strates sociales. - réalisation : Laurence Malonda - invités : Johan Faerber Editeur, essayiste, critique littéraire.; Marie Sorbier Productrice du "Point Culture" sur France Culture, et rédactrice en chef de I/O

durée : 00:27:42 - Les Midis de Culture - par : Marie Labory - Au programme du débat critique, de la littérature, avec Sorj Chalandon pour son "Le livre de Kells", et Laura Vazquez pour "Les Forces". - réalisation : Laurence Malonda - invités : Marie Sorbier Productrice du "Point Culture" sur France Culture, et rédactrice en chef de I/O; Johan Faerber Editeur, essayiste, critique littéraire.

durée : 00:13:50 - Les Midis de Culture - par : Marie Labory - Nos critiques discutent du dernier livre de Sorj Chalandon, "Le livre de Kells". S'inspirant de son expérience personnelle, l'auteur raconte l'histoire d'une jeunesse engagée. - réalisation : Laurence Malonda - invités : Johan Faerber Editeur, essayiste, critique littéraire.; Marie Sorbier Productrice du "Point Culture" sur France Culture, et rédactrice en chef de I/O

While Ghost of Yotei has gone gold and is now right around the corner, other segments of PlayStation Studios are on far less sturdy ground. Fairgames (or Fairgame$, if you like marketing) is seemingly the latest victim of an unprecedented run of bad decision-making, execution, and leadership within Sony's first party, as the upcoming shooter has shed its director, often (though not always) a dire sign for any project. Taken with recent reports (from this very show) of poor internal playtesting -- all the while Haven has already shed its major front-facing face and co-founder Jade Raymond -- we simply have to wonder whether Fairgames will ever launch at all. And if it does, does it have any potential to succeed whatsoever? Other news this week includes the rumored reemergence of Insomniac's Wolverine project, downward-revised SSD space for upcoming PS5 consoles, a fresh look at the promising Uncharted-like IO title 007: First Light, and much more. Then: Listener inquiries! Does Naughty Dog actually represent the pinnacle of game dev? How much can people twist themselves into a knot to justify piracy? What kind of pressure are studios and publishers under to adopt AI solutions? Will "Alleghany Hogs" catch on around the world? Please keep in mind that our timestamps are approximate, and will often be slightly off due to dynamic ad placement. 0:00:00 - Intro0:32:42 - Shoutout Preston0:40:47 - "Please clean up after your dog"0:52:10 - Let em oink0:54:16 - Chronos helmet = penis?0:55:36 - MGS3 correction0:56:34 - Ghost of Yotei goes gold1:03:22 - Fairgames creative director leave Haven1:28:24 - Wolverine rumors1:47:23 - PS5 reducing storage space on new units2:02:18 - 007 First Light gameplay revealed2:14:27 - IO may not publish an external game again after MindsEye2:19:13 - Hollow Knight SIlksong is only $202:27:57 - Capcom president says consoles are too becoming too expensive2:34:55 - Pragmata is not a Mega Man game2:37:01 - More games coming to PS42:44:57 - New live-action Tomb Raider2:47:04 - What We're Playing3:29:04 - Emulating new games3:44:41 - Why is Naughty Dog one of the best?3:53:42 - Call of Duty changing course on skins?4:00:24 - World's first platinum4:04:38 - Sony's pressure to integrate AI4:09:31 - Grading the show at the end Learn more about your ad choices. Visit podcastchoices.com/adchoices

Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.”  Our full disclosures are available in the transcript of this episode.  And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%.  And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting.  So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL  for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course.  And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media:        @ASCO on X (formerly Twitter)        ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck  Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera    

Samuel Beek is the Chief Product Officer at VEED.IO, one of the world's fastest-growing online video editing platforms. With a strong background in engineering and design, Sam combines creativity with strategic thinking to build tools that empower millions of content creators globally. On The Menu:1. Creative pragmatism philosophy in product decision-making2. AI-first approach to video editing innovation3. Growth hacking through Google search trend analysis4. Building VEED's ChatGPT store integration success5. Cross-departmental collaboration between product, engineering, and marketing6. Social media addiction challenges for tech leaders7. Future vision for AI-generated versus human-created contentClick here for a free trial: https://bit.ly/495qC9UFollow us on social media to hear from us more -Facebook- https://bit.ly/3ZYLiewInstagram- https://bit.ly/3UsdrtfLinkedin- https://bit.ly/43pdmdUTwitter- https://bit.ly/43qPvKXPinterest- https://bit.ly/3KOOa9uHappy creating!#SamuelBeek #Veed #Outgrow #Marketing #Shipping #MarketerOfTheMonth #Podcastoftheday #Marketingpodcast

Maksym Tkach, Chief Technology Officer at Frogo, sits down with us to discuss the company's breakthrough innovations in fraud prevention. From solving the hardest latency challenges in real-time detection to building a scalable, cloud-native architecture with Go and microservices, he shares how Frogo became the trusted partner for high-risk industries like fintech and iGaming. What's the biggest technical challenge you solved while building Frogo's real-time fraud detection engine? That's a great question. The single biggest challenge was resolving the fundamental conflict between detection complexity and real-time performance. Our clients, especially in fintech and iGaming, need to evaluate dozens, sometimes hundreds of data points and rules in a single transaction. But they also have strict SLAs, often under 500 milliseconds, because any added latency directly costs them money in lost conversions or rejected transactions. Doing both seemed impossible. Our breakthrough came when we broke the problem down into two parts: rule orchestration and data retrieval. For rule orchestration, we found that standard sequential rule engines were too slow. Many rules could be run in parallel, but some depended on the output of others. To solve this, my team and I designed a proprietary dependency graph execution engine we call 'LTee'. It stands for Layered Tree. Before processing a transaction, LTee analyses the entire rule set and organises it into layers. Layer 1 contains all independent rules that can be executed in parallel immediately. Layer 2 contains rules that depend on Layer 1's results, and so on. This model allows us to achieve maximum parallelisation while respecting data dependencies. In the worst case, it runs sequentially but for most transactions, it dramatically reduces execution time. For data retrieval, the bottleneck was calculating complex aggregations on the fly, for example, 'What's the 95th percentile of this user's transaction amount over the last 7 days?'. Querying a traditional database for this during a transaction is a non-starter for our latency budget. So, we made a strategic trade-off. We use Aerospike as a specialised time-series aggregation store. We pre-calculate and store metrics like standard deviation, percentiles and averages across various time windows and granularities. It consumes more storage, but it turns a computationally expensive query into a simple, sub-millisecond key-value lookup. For high-cardinality counts, like 'how many distinct devices has this user logged in from?', we use the proprietary approach algorithm to get near-instant, memory-efficient estimates. By combining these solutions, we turned our engine from a sequential process into a highly parallelised system fueled by pre-computed data. The result was a reduction in our p99 latency from over 5000ms to under 300ms, even with complex rule sets. This didn't just meet our SLAs; it became our core competitive advantage and allowed us to win major clients who had previously found other systems to be too slow. Why did you choose Go and a microservice architecture, and how has it shaped Frogo's scalability? This was a foundational decision driven by our need for performance, reliability, and developer velocity. For the language, we chose Go for three specific reasons: 1. Exceptional Concurrency for Our Workload: Fraud detection is an I/O-bound problem. For a single API call, we might need to fetch user data from Aerospike, check a device fingerprint, and query a 3rd party service simultaneously. Go's goroutines are lightweight and perfect for this. We can fire off thousands of concurrent operations efficiently, which is key to keeping our latency low. A language with heavier threads, like Java, would have been far less resource-efficient for our specific use case. 2. Performance and Simplicity: We adhere to the KISS principle. Go is simple to read and write, which speeds up onboarding for new engineers and reduces bugs. Critically, i...

Beth GMs for Ellie, Crash, and Io. This episode: The Logistics Trio try to enjoy a lovely meal, but everything changes when the mob attacks. Follow this series on… ▶ RSS: https://aaronbsmith.com/cogwheel/tag/gurpswars/podcast ▶ Patreon: https://www.patreon.com/cogwheelgaming ▶ Mastodon: https://is.aaronbsmith.com/@cogwheel Not on Mastodon? Consider these instances: gamepad.club dice.camp mastodon.art chirp.enworld.org tabletop.vip MP3 Download: GURPS Wars S1 Ep … Continue reading "GURPS Wars S1 Ep 77: Face Chair"

NÚKIB varuje před čínskými technologiemi – hrozba pro data i infrastrukturu. Vysvětlíme, co varování znamená pro firmy i jednotlivce. Podíváme se také na kyberútok na Jaguar Land Rover, který zastavil výrobu po celém světě, rekordní DDoS útok 11,5 Tbps proti Cloudflare, novou kritickou zranitelnost v TP-Link routerech a na to, proč globální výdaje na kyberbezpečnost v roce 2025 vystřelí na rekordních 213 miliard dolarů. Na závěr vás pozveme na livestream Rodina – základ kyberbezpečnosti v rámci akce Týden pro digitální Česko.

- Premi il tasto PLAY per ascoltare la catechesi del giorno e condividi con altri se vuoi -+ Dal Salmo 12 +RIT: Gioisco pienamente nel Signore.Guarda, rispondimi, Signore, mio Dio,conserva la luce ai miei occhi.  RIT: Gioisco pienamente nel Signore.Io nella tua fedeltà ho confidato;esulterà il mio cuore nella tua salvezza,canterò al Signore, che mi ha beneficato.  RIT: Gioisco pienamente nel Signore.Parola del Signore.

Pioneros como Gal Costa y Caetano, Stan Getz, Gilberto o Jobim y continuadores de la MPB, la chanson, la canción melódica italiana o la latinoamericana.Coração Vagabundo — GAL COSTA,CAETANO VELOSO, DomingoCorcovado (Quiet Nights of Quiet Stars) — STAN GETZ, JOÃO GILBERTO, ASTRUD GILBERTO, ANTÔNIO CARLOS JOBIM, Getz/GilbertoRio — NAY PORTTELA, RioIo & Te — DAVIDE ESPOSITO, CARLA BRUNI, Io & TeMalemolencia — CÉU, CéuSains et saufs — ZAZ, Sains et saufsWhy Should I Smile — ROSEAUX, MELISSA LAVEAUX, Roseaux IIISaveur Solaire — GABRIELLA LIMA, LEO MIDDEA, Sabor SolaireFado Crioulo — NANCY VIEIRA, ANTÓNIO ZAMBUJO, GenteLa Pomena — GABI HARTMANN, La femme aux yeux de selCan We Pretend — BILL WITHERS, 'JustmentsBehind the Curtain — IBEYI, IbeyiDança da Solidao — LUIZ MURÁ, SolitudeUn Amor - Intro — MARIA RODÉS, SIMON SMITH, También Esto Pasará (BSO)Llegas tú — MUERDO, SinvergüenzaPourquoi tu vis — PINK MARTINI, Bella CiaoEscuchar audio

[Croatian: Three hundred and eighty-three – Middle of nowhere] Go grab a friend and tell them that Io's back! To celebrate the great reunion, Michael and Io deliver a show... LEARN MORE The post Tristo osamdeset i tri – Bogu iza nogu appeared first on babble POP!.

若說90年代Sentra CE、HV是以豪華博得眾人青睞，Mitsubishi第五代Lancer中的1.8車型Virage則是運動房車的代表，尤其是之後的Sports-Mode手自排更是紅透台灣車壇，就算是排氣量超過1800c.c.不利稅制，銷售依舊強強滾！開車上路，右手總是要”拍、拍、拍”撥一撥排檔桿換一下檔位才有fu，之後還推出iO運動車型，在路上絕夠吸睛。除了1.8的Virage外，當時該車系還推出以家庭溫馨為訴求的Lancer 1.6，同樣獲得不錯的迴響，此般分進合擊的策略，成功開創出國產第五代Lancer車系的銷售榮景。還記得這段故事嗎？一起來回憶吧！ #行動星球 #島叔聊天室 #Virage #Lancer #SportsMode #手自排 #Mitsubishi #EVO #Celsior #島耕作 -- Hosting provided by SoundOn

ぬるぽ放送局おたより投稿フォーム https://forms.gle/6tbmBzK6wbyavJG47 2025年9月パワープレイ 「U.N.オーエンはXSなのさ？」 編曲：gaburyu 原曲：東方紅魔郷 / U.N.オーエンは彼女なのか？ 収録アルバム：TOHO BOOTLEGS 9 2025・5・5 Release https://www.iosysos.com/discographyportal.php?cdno=IO-0341 番組時間：47分57秒 出演者：夕野ヨシミ、たくや VOICEVOX:ずんだもん VOICEVOX:四国めたん ---- 2025/8/28に公開録音したものを配信いたします。 ラジオ記事はリスナーのEEチャンピオンさんが書いてくれているので楽してます。 ＜オープニング＞ ・夏休みおわりましたねー ・絵日記は書きましたか？ ・秋ですね ・北海道の秋は2週間くらい ・さんま食べたい ・シャインマスカットを冷凍して来年の夏に ・まだ、母親生きてますけどね ・母上見てるー？ ・イオシスくんの活動情報 ・ゲーム実況をたくさんやってます ・生放送は、週に11個 ・お仕事は、まだ詰め込めば何とかなります ・簡単な計算もグーグルクロームで ・M3は、どうなってしまうのか ・秋季例大祭もあります ・ぬるぽ詰め合わせは3枚の増産 ・最近は店舗に並ばない ・ｶﾞﾊﾊ ＜Aパート＞ ・ふつおたです ・スーパー稲刈りシーズン ・新米が食べたいよー ・マイクラだった ・やはり、農家さんに作ってもらわなと ・全部いいね付けますから ・もう一回いいねできる ・ほかえりー ・『RRR』と『バーフバリ』二部作が無料放送 ・イースⅠ、Ⅱみたいな感じ ・バーフバリ序・破・Q ・おすすめYouTubeチャンネル ・リドラの謎解きチャンネル ・最終問題1万点 ＜Bパート＞ ・みつをたです ・8ｔ燃えちゃったんですか？ ・どうでもいいでしょう始まりました ・え？ドムドムバーガー知らない？知らないかー ・入院しててもみつをたは送れるんだなー ・また、すき家の話なんですけど ・出汁が香る茶 ・デフォで出てくるみそ汁はありがたい ・平成一桁ガチババア ・2本撮りの2本目なのに時事ネタ書いちゃった ・創作昔話ゴンキツネ ・毎月1回なのかな？ ・きんたま串刺しで思い出した美唄焼き鳥 ・とりとめがなくなってきたのでおわろう ＜エンディング＞ ・玉の話を続けて27年 ・記念に玉取りますか ・意識が朦朧としてる ・もう、こんな時間なんだ ・22時からやってこの時間？？

Gaetano Savatteri"Il gatto che prendeva il treno"Conversazione sulla magia delle stazioniGaetano Savatteri dialoga con Andrea CamilleriBibliotheka Edizioniwww.bibliotheka.itRicordo una volta che arrivai a Palermo con il vagone-letto da Roma. Dovevo aspettare la coincidenza per Agrigento. Notai un gatto bianco e nero che si affrettava verso il treno. Io pensavo continuasse il suo cammino lungo la banchina, ma all'improvviso salì.Si avvicinava il momento della partenza, c'era già il capostazione con la paletta, presi coraggio e mi avvicinai: “Senta su questo treno è salito un gatto”. Non batté ciglio. Mi disse: “Com'era?”. “Bianco e nero”. “Non si preoccupi, disse, scende a Termini Imerese”.Durante la mezz'ora di viaggio tra Palermo e Termini cercai il gatto, ma non ve n'era traccia. Affacciato al finestrino, alla stazione di Termini Imerese, lo vidi scendere. Allora chiesi al controllore: “Ma c'era un gatto su questo treno, l'ha visto?”. “Non si preoccupi”, mi disse il controllore, “riprende stasera il treno delle otto per Palermo”.Gaetano Savatteri giornalista e scrittore, è nato a Milano nel 1964 da genitori di Racalmuto, e a dodici anni è tornato con la famiglia in Sicilia.Ha lavorato al Giornale di Sicilia, al quotidiano L'Indipendente, dove è stato inviato speciale, in seguito al Tg3, al Tg5 e a Rete 4.Dai romanzi e racconti che hanno per protagonista il giornalista e investigatore Saverio Lamanna, è stata tratta la serie televisiva Màkari con protagonista Claudio Gioè.Nel 2003 ha ricevuto con Camilleri il Premio Racalmare-Leonardo Sciascia. IL POSTO DELLE PAROLEascoltare fa pensarewww.ilpostodelleparole.itDiventa un supporter di questo podcast: https://www.spreaker.com/podcast/il-posto-delle-parole--1487855/support.

Chiara Giaccardi, Mauro Magatti"Macchine celibi"Meccanizzare l'umano o umanizzare il mondo?Edizioni del Mulinowww.mulino.itSiamo nell'epoca delle macchine celibi, dove l'essere umano viene modellato da ciò che lui stesso ha costruito. La via d'uscita sta nel recuperare ciò che la modernità ha emarginato: il dialogo, il pensiero, lo spirito. Perché la felicità non è celibe (e nemmeno la libertà).Cosa resta oggi della modernità definita «liquida» da Zygmunt Bauman? Il modello di sviluppo che ha dominato il passaggio di secolo è ormai tramontato. Come tenere insieme, allora, una società sempre più grande e frammentata, che si sbarazza dell'ordine morale tradizionale in nome della libertà personale? Il digitale, che si propone come antidoto alle spinte disgregatrici della nostra epoca, è allo stesso tempo un potente catalizzatore di nuovi problemi. Il risultato è paradossale: massima efficienza e massimo caos comunicativo coesistono. E mentre le macchine intelligenti diventano sempre più simili all'uomo, l'uomo rischia di regredire a «macchina celibe»: un Io isolato, performante, privo di legami e incapace di riconoscere l'altro. Questo libro ci richiama all'urgenza di un pensiero nuovo, a partire dalla riscoperta di una «politica dello spirito» capace di restituire senso, legami e futuro alle nostre società. Siamo a un bivio: sta a noi scegliere la direzione.Chiara Giaccardi insegna Sociologia e Antropologia dei media all'Università Cattolica di Milano, dove dirige anche la rivista «Comunicazioni Sociali». Mauro Magatti insegna Sociologia all'Università Cattolica di Milano. È editorialista del «Corriere della Sera» e di «Avvenire». Insieme hanno pubblicato per il Mulino «La scommessa cattolica» (2019), «Nella fine è l'inizio» (2020), «Supersocietà» (2022) e «Generare libertà» (2024).IL POSTO DELLE PAROLEascoltare fa pensarewww.ilpostodelleparole.itDiventa un supporter di questo podcast: https://www.spreaker.com/podcast/il-posto-delle-parole--1487855/support.

durée : 00:12:10 - Les Midis de Culture - par : Marie Labory - Dans "Au Grand Jamais", Jakuta Alikavazovic tisse un récit où les frontières entre passé et présent se dissolvent, explorant avec une délicatesse saisissante les méandres de la mémoire et des émotions. À travers une écriture poétique et introspective, l'auteure nous invite à un voyage intime. - réalisation : Laurence Malonda - invités : Marie Sorbier Productrice du "Point Culture" sur France Culture, et rédactrice en chef de I/O; Virginie Bloch-Lainé Productrice à France Culture, critique littéraire, romancière.

durée : 00:26:46 - Les Midis de Culture - par : Marie Labory - Au programme du débat critique, émotions et littérature, avec Emmanuel Carrère et son dernier livre "Kolkhoze", et Jakuta Alikavazovic pour "Au Grand Jamais". - réalisation : Laurence Malonda - invités : Marie Sorbier Productrice du "Point Culture" sur France Culture, et rédactrice en chef de I/O; Virginie Bloch-Lainé Productrice à France Culture, critique littéraire, romancière.

durée : 00:14:38 - Les Midis de Culture - par : Marie Labory - Emmanuel Carrère plonge au cœur de son histoire familiale, tissant un récit à la fois intime et profondément romanesque. Au centre de ce portrait sans concession se dessine la figure d'Hélène Carrère d'Encausse, son indomptable mère, académicienne disparue en 2023. - réalisation : Laurence Malonda - invités : Marie Sorbier Productrice du "Point Culture" sur France Culture, et rédactrice en chef de I/O; Virginie Bloch-Lainé Productrice à France Culture, critique littéraire, romancière.

Ellie GMs for Beth, Crash, Io, & Jen. This episode: The party spend the night in the tower and wake to find a familiar guest, followed by another, larger guest. Follow this series on… ▶RSS: https://aaronbsmith.com/cogwheel/tag/plus-ultra/feed/ ▶Patreon: https://www.patreon.com/cogwheelgaming ▶Mastodon: https://is.aaronbsmith.com/@cogwheel Not on Mastodon? Consider these instances: gamepad.club dice.camp mastodon.art MP3 Download: Plus Ultra Ep 26: … Continue reading "Plus Ultra Ep 26: Distant Early Warning (Cypher System)"

In this episode, Anna Rose and Tarun Chitra chat with Huijia (Rachel) Lin from the University of Washington to explore indistinguishability obfuscation (iO), often described as the 'holy grail of cryptography'. iO is a powerful primitive that, if fully realised, could have profound implications for privacy tech as a whole. Rachel helps break down the concept for listeners who may already be familiar with ZK, FHE and TEEs, clarifying how iO differs but also some of the similarities in the assumptions upon which it is based. Rachel also explains how it differs from similar concepts: garbled circuits and functional encryption. The discussion covers the evolution of iO research in her work over the last decade, how the cryptographic assumptions have hardened since that time, and what iO can offer in terms of precise, controlled information revelation. Related links: Indistinguishability obfuscation from well-founded assumptions Indistinguishability Obfuscation from DDH-like Assumptions on Constant-Degree Graded Encodings On Lattices, Learning with Errors, Random Linear Codes, and Cryptography How to Use Indistinguishability Obfuscation: Deniable Encryption, and More Functional Encryption for Quadratic Functions, and Applications to Predicate Encryption Garbled circuit ZK Whiteboard Season 3 just kicked off with our first Module all about Hash Functions! In this, we have host Nico and guest JP Aumauson walk us through how to build a Hash Function. JP was also previously on the show to discuss the topic, you can see his episode here! See all Whiteboard Sessions including previous seasons here.    **If you like what we do:** * Find all our links here! @ZeroKnowledge | Linktree * Subscribe to our podcast

The sicker the patient, the more likely an IO line is the right choice. In emergencies such as cardiac arrest or hemorrhagic shock, the speed and reliability of IO access outshine traditional intravenous (IV) or central line placements. There's virtually no resuscitation medication or blood product that cannot be administered through an IO, making it indispensable in life-threatening scenarios. The post REBEL Core Cast 140.0: The Power and Limitations of Intraosseous Lines in Emergency Medicine appeared first on REBEL EM - Emergency Medicine Blog.

Beth GMs for Ellie, Crash, and Io. This episode: The Logistics Trio split the party, with Antuxa learning more from one crime boss while Ran and Sen scope out a restaurant frequented by another. Follow this series on… ▶ RSS: https://aaronbsmith.com/cogwheel/tag/gurpswars/podcast ▶ Patreon: https://www.patreon.com/cogwheelgaming ▶ Mastodon: https://is.aaronbsmith.com/@cogwheel Not on Mastodon? Consider these instances: gamepad.club dice.camp … Continue reading "GURPS Wars S1 Ep 76: Blue Orchid"

Predicazione espositiva del Pastore Jonathan Whitman di Matteo capitolo 8 versetti da 5 a 13. Registrata presso il Centro Evangelico Battista di Perugia il 17 agosto 2025.Titolo del messaggio: "Il Re che guarisce - Tre dimostrazioni che Gesù è Re sopra le nostre infermità (2a Parte: Gesù e la Fede del Centurione)"MATTEO 8 V5-135 Quando Gesù fu entrato in Capernaum, un centurione venne da lui, pregandolo e dicendo: 6 «Signore, il mio servo giace in casa paralitico e soffre moltissimo». 7 Gesù gli disse: «Io verrò e lo guarirò». 8 Ma il centurione rispose: «Signore, io non sono degno che tu entri sotto il mio tetto, ma di' soltanto una parola e il mio servo sarà guarito. 9 Perché anche io sono uomo sottoposto ad altri e ho sotto di me dei soldati; e dico a uno: "Va'", ed egli va; e a un altro: "Vieni", ed egli viene; e al mio servo: "Fa' questo", ed egli lo fa». 10 Gesù, udito questo, ne restò meravigliato, e disse a quelli che lo seguivano: «Io vi dico in verità che in nessuno, in Israele, ho trovato una fede così grande! 11 E io vi dico che molti verranno da Oriente e da Occidente e si metteranno a tavola con Abraamo, Isacco e Giacobbe nel regno dei cieli, 12 ma i figli del regno saranno gettati nelle tenebre di fuori. Là ci sarà pianto e stridor di denti». 13 Gesù disse al centurione: «Va' e ti sia fatto come hai creduto». E il servitore fu guarito in quella stessa ora.

Caitlin Cannon on "Slut Energy," Her 'Love Addict' Album, and Songwriting in PrisonsDive deep with Americana artist Caitlin Cannon as she joins Jason English for a raw and unfiltered conversation. Caitlin opens up about her provocative appearance on the Kill Tony show, the "slut energy" she brings to her music, and navigating the industry in her forties. She discusses the inspiration behind her powerful new album, "Love Addict," exploring themes of loneliness, relationships, and self-discovery. Caitlin also shares the profound story behind her work with the Beyond Bars program, teaching songwriting to inmates, and how her brother's incarceration has shaped her art. This is a can't-miss episode about music, trauma, and radical honesty.Proposed Chapters:00:00 - Life on Tour & ADHD02:30 - That Kill Tony "Slut Energy" Moment06:30 - Trauma, Religion & the Americana Scene09:00 - Rebelling Against Industry Ageism13:30 - Inside the "Love Addict" Album15:15 - "You're Losing Me": Loneliness & Divorce22:15 - Relationship Status: "Married to the Music"28:15 - The Story Behind "Jesus Is My Lover"38:30 - The Terrifying Intimacy of Co-Writing47:00 - Beyond Bars: Teaching Songwriting in Prisons52:30 - "Waiting": A Song for Her Brother58:00 - What Caitlin Cannon is Most Curious About

Get this full episode and support the pod! ⁠Join our Patreon ⁠for $3 a month for full episodes an $5 bonus eps, back log eps, and exclusive premium content!⁠Join the Discord community⁠Dive into our discord channel to connect with fellow fans, discuss your favorite episodes, and meet the hosts of the show!Another fun fudged up week of Fudgecast and we welcome back Alonso Ramirez and Kristen Aviles to the pod! We chat'n'prov about heists, sleep away camps, she-wolfs in closets and more!We're doing it LIVE with Kyle Bethea and Ollie Hobson this Friday at 7:30 pm at iO! A Classic Friday Night Fudge and Friends! Use code IMPROVPERVERT for $5 off tix!See Kristen and Alonso together at Splatter!See Kristen, Alonso, and Damian with ESCÁNDALO!Hosts:Hosts:⁠ ⁠Damian Anaya⁠⁠,⁠ ⁠Tim Lyons⁠⁠,

We continue our conversation with Mike Atkins and David McDermott, discussing IO-based combination therapy in RCC.

In episode 103 we chat with Drs. Andrea Bazzoli and Ian Hughes to explore their recent publication in the Journal of Business and Psychology. The conversation dives deep into how financial stress fluctuates over time, why small monetary changes—not just big windfalls—can significantly impact employee well-being, and how the nonlinear nature of these relationships challenge traditional assumptions in workplace psychology.We discuss:* The surprising power of small financial fluctuations* Why lump-sum bonuses might not reduce stress as expected* How macroeconomic policies intersect with organizational behavior* Actionable strategies for managers to support financially stressed employeesWhether you're an I-O psychologist, HR leader, or just curious about the psychology of money at work, this episode offers data-driven insights and practical takeaways for improving employee well-being. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit healthywork.substack.com

In this episode, Host Jason English sits down with Virginia native and Nashville-based artist Levi Foster, a traditional country voice with an old soul. Levi shares his incredible journey from living in his van to signing a publishing deal and writing over 300 songs. He discusses the inspiration behind his debut album, "We Made Fire," the classic country vibes of his duet "Emerald Eyes," and how a spontaneous TikTok video of him singing pop songs as Johnny Cash unexpectedly launched his brand. In an exciting announcement, Levi reveals his dream collaboration—an upcoming full-length record produced by the legendary Shooter Jennings. This is a conversation about chasing a dream with conviction, the surprising paths to success, and staying curious through it all.Chapters:[00:00:00] - Welcome to Curious Goldfish[00:01:15] - Growing Up in the Shadow of Liberty University[00:02:45] - The "On a Whim" Move to Nashville[00:04:10] - Making a Pact: Living in a Van to Chase the Dream[00:04:45] - How a Publishing Deal Changed Everything[00:06:15] - The Songwriter's Grind: Writing Over 300 Songs[00:11:15] - Behind the New Album: "We Made Fire"[00:14:15] - The Story of "Emerald Eyes" with Gloria[00:17:05] - Reluctantly Embracing TikTok & Social Media[00:20:05] - What He Thinks of Brendan Abernathy's Viral Moment[00:23:30] - The Dream Collaboration: Recording with Shooter Jennings[00:25:20] - Be Curious: What Drives Levi Foster?

Marty shares information about the new - but not existent - Vivo Vision; what they've told us and what we still don't knowToday's ProNote: Vivo VisionVivo Vision Mixed-Reality Headset Steps Up to Apple, but Still a Tough Sellhttps://www.cnet.com/tech/computing/vivo-vision-mixed-reality-headset-steps-up-to-apple-but-still-a-tough-sellVivo's Vision Pro clone costs $1,400 and weighs 398ghttps://9to5mac.com/2025/08/21/vivos-vision-pro-clone-costs-1400-and-weighs-398g/What it isName: Vivo Vision a.k.a. Vision Discovery Edition; some coverage uses “Explorer Edition”.Status: In-store demos only across ~a dozen locations in China; no confirmed preorders/ship date.Hardware fast factsDisplays: Dual micro-OLED, 3,840×3,552 per eye; “8K binocular” marketing; 94% DCI-P3, factory ΔE less than 2 color.Weight: ~398 g not including external battery.Passthrough: Full-color, quoted ~13 ms latency.Chip/OS: Snapdragon XR2+ Gen 2 running OriginOS Vision — Android-based.I/O & comfort: Gaze + pinch with hand tracking; four light-seal sizes, eight foam pads; external tethered battery.Price & availabilityTarget price: Vivo execs suggest ≈ ¥10,000 ~$1,400; significantly under Vision Pro's $3,499. But pricing is not final and availability is TBD.Compare: Vivo Vision vs. Apple Vision ProWeight: ~398 g vs. AVP's ~600–650 g—comfort could be a win for Vivo.Compute: XR2+ Gen 2 Android vs. Apple M-series visionOS — Apple likely leads raw performance and ecosystem today.Display claims: Vivo's per-eye resolution is competitive; refresh rate/brightness not clearly stated.Ecosystem: AVP has a year-plus head start and tighter integrations; Vivo's app store/content story is unclear.What's missingShip timeline: No preorder date, no shipping window.Battery life: No hours-of-use claims for the external pack.Display specs: Refresh rate and brightness nits not published in official materials.FoV reality: Marketing mentions “panoramic/180°,” but no standardized FoV spec H/diag yet.Controllers/content: Hand tracking is featured; controller support and content partners aren't spelled out.Global plans: No word on international release or certifications.Reality check: Demo-only today; some reports prematurely called it a “launch.” Useful to underscore for listeners.Email: ThePodTalkNetwork@gmail.comWebsite: ThePodtalk.Net

Il verbo PIACERE è uno dei verbi più particolari e complessi della lingua italiana, spesso fonte di confusione per gli studenti stranieri. A differenza dei verbi tradizionali, PIACERE ha una struttura grammaticale invertita che richiede una comprensione speciale del suo funzionamento. Questa guida completa ti aiuterà a padroneggiare completamente questo verbo fondamentale e gli altri verbi che si comportano come lui. Il Verbo PIACERE e simili: Guida per Usarli Correttamente La Struttura Particolare del Verbo PIACERE Il verbo PIACERE funziona in modo completamente diverso rispetto ai verbi normali italiani. Mentre i verbi tradizionali seguono la struttura Soggetto + Verbo + Oggetto Diretto, il verbo PIACERE utilizza la struttura Soggetto + Verbo + Oggetto Indiretto. Confronto tra strutture: • Verbo normale: "Io (soggetto) mangio (verbo) la pizza (oggetto diretto)"• Verbo PIACERE: "La pizza (soggetto) piace (verbo) a me (oggetto indiretto)" Questa particolarità rende PIACERE un verbo di percezione e sensazione che descrive un'emozione che qualcosa o qualcuno provoca in una persona. La persona non compie un'azione diretta, ma è il destinatario di un sentimento di piacere provocato da qualcos'altro. I Pronomi di Oggetto Indiretto con PIACERE Il verbo PIACERE richiede sempre l'uso di pronomi di oggetto indiretto o della preposizione "A" per indicare chi "riceve" il piacere. I pronomi "mi, ti, gli..." sostituiscono le forme complete "a me, a te, a lui" e rendono la comunicazione più fluida e naturale. Tabella completa dei pronomi: • MI piace = piace A ME (prima persona singolare)• TI piace = piace A TE (seconda persona singolare)• GLI piace = piace A LUI (terza persona singolare maschile)• LE piace = piace A LEI (terza persona singolare femminile)• CI piace = piace A NOI (prima persona plurale)• VI piace = piace A VOI (seconda persona plurale)• GLI piace = piace A LORO (terza persona plurale) Esempi pratici: • "Mi piace il caffè" = "Il caffè piace a me" • "Ti piacciono i libri" = "I libri piacciono a te" • "Gli piace la musica" = "La musica piace a lui" L'Uso con Nomi Propri e la Preposizione A Quando il destinatario del piacere è espresso con un nome proprio o un sostantivo, è invece obbligatorio utilizzare la preposizione "A". Questa regola è fondamentale per la correttezza grammaticale. Esempi con nomi propri: • "La pizza piace a Maria" ✓ • "Maria piace la pizza" ✗ • "A Paolo piacciono i dolci" ✓ • "Paolo piacciono i dolci" ✗ Esempi con sostantivi: • "Il calcio piace ai ragazzi" • "La musica classica piace agli anziani" • "I videogiochi piacciono ai bambini" Esistono solo PIACE e PIACCIONO? Il verbo PIACERE si accorda sempre con il soggetto grammaticale (quello che provoca il piacere), non con la persona che riceve l'emozione (oggetto indiretto). Però attenzione: il verbo PIACERE può essere coniugato in tutte le persone! Dipende solo a chi (o cosa) causa il piacere. PIACE (terza persona singolare): • Si usa quando il soggetto è singolare • "Mi piace il gelato" (un gelato) • "Ti piace questa canzone" (una canzone) • "Gli piace cucinare" (un'attività - infinito) PIACCIONO (terza persona plurale): • Si usa quando il soggetto è plurale • "Mi piacciono i gelati" (più gelati) • "Ti piacciono queste canzoni" (più canzoni) • "Gli piacciono i film" (più film) Ma anche... Mi piaci tu. Davvero ti piaccio io? Voi, miei cari LearnAmici, mi piacete tantissimo. Il Verbo PIACERE nei Tempi Composti Nei tempi composti, il verbo PIACERE utilizza sempre l'ausiliare ESSERE e il participio passato si accorda con il soggetto grammaticale (quello che provoca il piacere). Questa regola è essenziale per formare correttamente passato prossimo, trapassato prossimo e altri tempi composti. Passato Prossimo: • "Mi è piaciuto il film" (un film - maschile singolare) • "Mi è piaciuta la pizza" (una pizza - femminile singolare)

Nestlemania and JC discuss...Naomi is pregant... What happens to the title?Io and Kabuki Warriors kinda trapped now.Why aren't they letting Nattie be a badass?Can we find new challengers for Seth Rollins?And we give our Forbidden Door predictions!All this and more ...this week on the Jobber Knocker Podcast.Check out the merchandise! https://www.teepublic.com/JobberKnockerFollow us on Twitter!@JobberKnocker@Nestlemania@JCoftheJK@TJoftheJK@RayRayoftheJK@DommyFeds33@Danyfab@SSJPegasusFollow us on Facebook & Instagram @JobberKnocker!Visit Jobberknocker.com for some great wrestling articles!

Get this full episode and support the pod! ⁠Join our Patreon ⁠for $3 a month for full episodes an $5 bonus eps, back log eps, and exclusive premium content!⁠Join the Discord community⁠Dive into our discord channel to connect with fellow fans, discuss your favorite episodes, and meet the hosts of the show!This week on the pod we've got two of our very best friends and improvisers Lawrence Collerd and Laurel Krabacher. We chat'n'prov about baby sitting, sausage, and the expedient passage of time.We're on the look out for our next FUDGE and Friends dates so keep your eyes glued for that date soon!Be sure to follow LSI for updates on their upcoming Cherry Street run!Check out My Man on Thursdays in August directed by Laurel at iO for two more shows!Performers:Hosts: ⁠Damian Anaya⁠, ⁠Tim Lyons⁠, and ⁠Dan White⁠

The fathers of IO therapy in RCC - Michael Atkins and David McDermott - join us to take a tour through IO development in RCC over the last 20 years.

In this episode, Andrew Mayne, Brian Brushwood, and Justin Robert Young tackle the whirlwind of AI news, starting with Google’s I/O announcements, particularly their impressive V O 3 image generation model. They then shift to OpenAI’s advancements and discuss the intriguing, yet mysterious, hardware collaboration between OpenAI and Johnny Ive’s design firm. The trio also […]

Get this full episode and support the pod! ⁠Join our Patreon ⁠for $3 a month for full episodes and $5 for Discord bonus eps, backlog eps, and exclusive premium content!⁠Join the Discord community⁠Dive into our discord channel to connect with fellow fans, discuss your favorite episodes, and meet the hosts of the show!Sup Pervs!This week on the cast, we're joined by the hilarious Ella Nagle and Jake Prizant! We Chat'n'prov about spooky old antique signs, Roman torture devices, and AI-generated pizza commercials. You can follow Ella on socials to see when and where she's dropping some stand-up and improv lore around town!Check out Jake on Cream Boy Saturday nights at iO and Missed Call at the Annoyance! You can also see him on the smash hit Deli Boys on Hulu!